Research Article

Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation

Martin Risch,¹ Myriam Weber,² Sarah Thiel,² Kirsten Grossmann,^{3,4} Nadia Wohlwend,³ Thomas Lung,³ Dorothea Hillmann,³ Michael Ritzler,³ Francesca Ferrara,³ Susanna Bigler,⁵ Konrad Egli,⁵ Thomas Bodmer,⁵ Mauro Imperiali,⁶ Yacir Salimi,⁷ Felix Fleisch,⁸ Alexia Cusini,⁸ Harald Renz,⁹ Philipp Kohler,¹⁰ Pietro Vernazza,¹⁰ Christian R. Kahlert,⁰,^{10,11} Matthias Paprotny,² and Lorenz Risch,⁰,^{3,4,12}

¹Zentrallabor, Kantonsspital Graubünden, Loësstrasse 170, 7000 Chur, Switzerland

²Liechtensteinisches Landesspital, Heiligkreuz, 9490 Vaduz, Liechtenstein

³Labormedizinisches Zentrum Dr. Risch, Wuhrstrasse 14, 9490 Vaduz, Liechtenstein

⁴Private Universität im Fürstentum Liechtenstein, Dorfstrasse, 9495 Triesen, Liechtenstein

⁵Labormedizinisches Zentrum Dr. Risch, Waldeggstrasse 37, 3097 Liebefeld, Switzerland

⁶Centro Medicina di Laboratorio Dr. Risch, Via Arbostra 2, 6963 Pregassona, Switzerland

⁷Clm Dr. Risch Arc Lémanique SA, Chemin de l'Esparcette 10, 1023 Crissier, Switzerland

⁸Division of Infectious Diseases, Cantonal Hospital Chur, Loësstrasse 170, 7000 Chur, Switzerland

⁹Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, University Hospital Giessen and Marburg, Baldingerstraße, 35043 Marburg, Germany

- ¹⁰Cantonal Hospital St. Gallen, Department of Infectious Diseases and Hospital Epidemiology, Rohrschacherstrasse 95, 9007 St. Gallen, Switzerland
- ¹¹Children's Hospital of Eastern Switzerland, Department of Infectious Diseases and Hospital Epidemiology, Claudiusstrasse 6, 9006 St. Gallen, Switzerland

¹²Center of Laboratory Medicine, University Institute of Clinical Chemistry, University of Bern, Inselspital, 3010 Bern, Switzerland

Correspondence should be addressed to Lorenz Risch; lorenzrisch@hotmail.com

Received 24 July 2020; Revised 13 October 2020; Accepted 22 October 2020; Published 18 November 2020

Academic Editor: Neelima Mishra

Copyright © 2020 Martin Risch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Knowledge of the sensitivities of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests beyond 35 days after the clinical onset of COVID-19 is insufficient. We aimed to describe positivity rate of SARS-CoV-2 assays employing three different measurement principles over a prolonged period. Two hundred sixty-eight samples from 180 symptomatic patients with COVID-19 and a reverse transcription polymerase chain reaction (RT-PCR) test followed by serological investigation of SARS-CoV-2 antibodies were included. We conducted three chemiluminescence (including electrochemiluminescence assay (ECLIA)), four enzyme-linked immunosorbent assay (ELISA), and one lateral flow immunoassay (LFIA) test formats. Positivity rates, as well as positive (PPVs) and negative predictive values (NPVs), were calculated for each week after the first clinical presentation for COVID-19. Furthermore, combinations of tests were assessed within an orthogonal testing approach employing two independent assays and predictive values were calculated. Heat maps were constructed to graphically illustrate operational test characteristics. During a follow-up period of more than 9 weeks, chemiluminescence assays and one ELISA IgG test showed stable positivity rates after the third week. With the exception of ECLIA, the PPVs of the other chemiluminescence assays were \geq 95% for COVID-19 only after the second week. ELISA and LFIA had somewhat lower PPVs. IgM exhibited insufficient predictive characteristics. An orthogonal testing approach provided PPVs \geq 95% for patients, even for tests with a low single test performance. After the second week, NPVs of all but IgM assays were \geq 95% for patients with low to moderate pretest probability. The confirmation of negative results using an

orthogonal algorithm with another assay provided lower NPVs than the single assays. When interpreting results from SARS-CoV-2 tests, the pretest probability, time of blood draw, and assay characteristics must be carefully considered. An orthogonal testing approach increases the accuracy of positive, but not negative, predictions.

1. Introduction

Coronavirus Disease 2019 (COVID-19) is a pandemic that has challenged healthcare systems worldwide [1]. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. Its diagnosis is based on clinical symptoms and signs, radiological imaging, detection of the virus with reverse transcription polymerase chain reaction (RT-PCR) or antigen testing mainly in respiratory specimens, and serological confirmation of SARS-CoV-2-specific antibodies in serum [3, 4]. Although RT-PCR has been reported to possess 100% specificity, it does not provide 100% sensitivity in diagnosing COVID-19 [5], due to issues related to the preanalytical sample quality as well as local and temporal changes in viral shedding [5-7]. In the clinic, serological testing has increasingly become important to clarify RT-PCR-negative patients with a high clinical suspicion of COVID-19 ("false negatives") [8]. Furthermore, serological testing has also become important for surveillance and tracing purposes to identify the disease prevalence in a distinct population or identify close contacts of patients with asymptomatic COVID-19 [9].

Recently, a Cochrane review systematically analyzed the sensitivity of different assays in diagnosing COVID-19 and concluded that the time since the onset of symptoms is a critical determinant of test sensitivity [3]. Antibody tests can play a useful role after the first week of symptom onset [3]. However, the authors obtained very little data to describe the sensitivity of the different tests after 35 days. The present study is aimed at describing the positivity rates of different serological tests after a diagnosis of COVID-19 for a prolonged period of up to 9 weeks.

2. Methods

2.1. Study Setting and Study Population. This retrospective study was conducted using anonymized samples. These samples were obtained from patients in Switzerland and the principality of Liechtenstein and sent to a binational group of medical laboratories (labormedizinische zentren Dr. Risch, Switzerland and Liechtenstein). Samples were included in the analysis when patients had a positive RT-PCR for COVID-19 prior to serum sampling. The vast majority of the RT-PCRpositive results was obtained during March and April 2020, and three further RT-PCR-positive results were obtained until June 12, 2020. The serum samples mainly originated from outpatient settings. During March and April, RT-PCR testing in Switzerland and Liechtenstein was offered to individuals presenting with a fever of 38°C and respiratory symptoms, whereas after April 2020, testing was offered to individuals displaying any possible COVID-19 symptom [10]. The study protocol was verified by the cantonal ethics boards of Zurich (BASEC Req-20-00587) and Eastern Switzerland (EKOS; BASEC Nr. Req-2020-00586). Informed consent for performing a laboratory analysis of anonymized samples was waived.

2.2. Laboratory Methods. For each serum sample, the age and sex of the individual, the type of clinical setting, and the number of days from sample collection to RT-PCR were available. Serum employed for testing was either freshly collected or stored for less than 3 months at -25°C. For antibody testing using the chemiluminescence technique, antibodies were tested with three chemiluminescence assays, four enzymelinked immunosorbent assays (ELISA), and one lateral flow immunoassay, as detailed in Table 1. The manufacturers' cut-off values as well as the imprecision of the assays are also shown in Table 1: COI (cut-off index) for electrochemiluminescence assay (ECLIA) and S/C (S/C = extinction of the patient sample divided by the extinction of the calibrator) for the other chemiluminescence (i.e., CMIA (chemiluminescent microparticle immunoassay) and LIA (luminescence immunoassay)) and ELISA assays. All tests were performed and analyzed according to the manufacturer's instructions. All assays were CE marked. Lab technicians reading the lateral flow test format were not aware of the RT-PCR result or the results of other antibody tests when manually reading the lateral flow test cassettes.

2.3. Statistical Methods. Continuous variables are presented as medians and interquartile ranges (IQRs), whereas proportions are presented as percentages and 95% confidence intervals (CIs). The positive rates of the different assays were calculated as fractions of positive results of all investigated samples from patients with positive RT-PCR results (i.e., sensitivity) at different weekly time periods after the first clinical presentation for COVID-19. Statistically significant differences in proportions were tested using the chi-square test. Furthermore, operative test characteristics stratified according to the time point of blood sampling and pretest probabilities were assessed by calculating negative (NPV) and positive (PPV) predictive values [11]. For this analysis, the following specificity values, as evaluated in another cohort investigated by some of the authors of this report in a cohort of 1002 healthcare workers without COVID-19 [12], were employed: 99.5% for the CMIA, 99.7% for the LIA, 99.9% for the ECLIA, 99.2% for the EI IgG ELISA, 99.2% for the EI IgA ELISA, 95.8% for the EDI IgG ELISA, 96.7% for the EDI IgM ELISA, 99.5% for the IgG LFIA, 95.6% for the IgM LFIA, and 95.2% for IgG and/or IgM in the LFIA. For an illustration of predictive values, heat maps were constructed to graphically display predictive values stratified according to the time point of blood sampling and pretest probability. Pretest probabilities were considered very low (1%; e.g., asymptomatic persons in very low prevalence regions), low (<10%; e.g., asymptomatic persons in low prevalence regions), moderate (10-25%; e.g., symptomatic persons with a suspicion

spike	
61 = sp	
en; (
ntig	
sid a	
cap	
nclec	ny).
= nu	rma
bulin; N = nucleoca	Ğ
buli	ldorf
oglo	ıken
unu	Den
l imi	logies, I
tota	nolo
y; Ig=total	ech
say;	ynex T
nt as	Dyn
rbei	zer (
nosc	naly
nmu	SA al
ed in	ELIS
linke	an
me-	SX is
enzyı	Ŭ.
ISA = enz	atior
ELIS	vari
ies. I	it of
bod	cien
anti	coeffi
V-2	V = co
S-Co	S: C
SAR	unit
nti-S	sub
ofa	1/S2
tion	in S
nina	rote
etern	lke p
or de	= spi
sts fc	/S2
id te	t: S1
loye	buni
Emp	l sul
Е 1: .	in S]
ABLI	rotei

Test acronym	Measurement principle	Test name	Manufacturer	Analyzer	Isotype	Target antigen	Cut-off	CV (%)
CMIA	Chemiluminescent microparticle immunoassay	SARS-CoV-2 IgG	Abbott Diagnostics, Baar, Switzerland	Architect i2000	IgG	z	≥1.4	3.6
ECLIA	Electrochemiluminescence assay	Elecsys® Anti-SARS-CoV-2	Roche Diagnostics, Rotkreuz, Switzerland	COBAS 6000	Total Ig	Z	>1	2.7
LIA	Luminescence immunoassay	LIAISON® SARS-CoV-2 S1/S2 IgG	Diasorin, Luzern, Switzerland	Liaison	IgG	S1/S2	>12	5.4
EI IgG	ELISA	EUROIMMUN Anti-SARS-CoV-2 ELISA IgG (EI IgG)	Euroimmun, Luzern, Switzerland	DSX	IgG	S1	≥1.1	3.6
EI IgA	ELISA	EUROIMMUN Anti-SARS-CoV-2 ELISA IgG (EI IgA)	Euroimmun, Luzern, Switzerland	DSX	IgA	S1	≥1.1	4.6
EDI IgG	ELISA	EDI TM Novel Coronavirus COVID-19 IgG	Epitope Diagnostics, Inc., San Diego, USA	DSX	IgG	Z	Manufacturer specific	11.2
EDI IgM	ELISA	EDI TM Novel Coronavirus COVID-19 IgM	Epitope Diagnostics, Inc., San Diego, USA	DSX	IgM	Z	Manufacturer specific	9.7
LFIA	Lateral flow immunoassay	SGTi-flex COVID-19 IgM/IgG	Sugentech Inc., Daejeon, South Korea	N/A	IgG/IgM	Z	Qualitative reading	N/A

TABLE 2: Positive samples among all investigated samples from patients with COVID-19 stratified according to time of serum sampling since the first clinical presentation. Positivity rates are given in brackets.

	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
LFIA IgG	14/34	14/31	14/18	15/19	14/18	16/25	29/38	18/32	5/7
	(41%)	(45%)	(78%)	(79%)	(78%)	(64%)	(76%)	(56%)	(71%)
LFIA IgM	18/34	23/31	14/18	14/19	11/18	8/25	15/38	8/32	2/7
	(53%)	(74%)	(78%)	(74%)	(61%)	(32%)	(39%)	(13%)	(29%)
LFIA IgG/IgM	19/34	24/31	16/18	16/19	15/18	18/25	31/38	19/32	6/7
	(56%)	(77%)	(89%)	(84%)	(83%)	(72%)	(82%)	(59%)	(86%)
EI ELISA IgG	11/23	7/19	6/6	9/10	16/17	23/26	35/39	32/38	39/40
	(48%)	(37%)	(100%)	(90%)	(94%)	(88%)	(90%)	(84%)	(98%)
EI ELISA IgA	11/23	12/19	6/8	9/10	14/15	21/26	32/38	29/38	13/16
	(48%)	(63%)	(75%)	(90%)	(93%)	(81%)	(84%)	(76%)	(81%)
EDI ELISA IgG	24/35	24/32	20/20	28/28	27/30	28/35	36/47	26/37	14/24
	(69%)	(75%)	(100%)	(100%)	(90%)	(80%)	(77%)	(70%)	(58%)
EDI ELISA IgM	21/35	17/32	19/20	11/26	13/30	9/35	15/47	6/37	3/24
	(60%)	(53%)	(95%)	(42%)	(43%)	(31%)	(32%)	(16%)	(13%)
ECLIA Ig	21/34	18/26	19/19	20/21	28/29	32/34	44/45	37/39	49/53
	(62%)	(69%)	(100%)	(95%)	(97%)	(94%)	(98%)	(95%)	(92%)
CMIA IgG	19/31	17/28	18/18	21/22	27/28	31/32	40/43	33/36	12/13
	(61%)	(61%)	(100%)	(95%)	(96%)	(97%)	(93%)	(92%)	(92%)
LIA IgG	17/32	14/28	16/18	18/21	26/28	27/32	42/44	32/38	24/26
	(53%)	(50%)	(89%)	(86%)	(93%)	(84%)	(95%)	(84%)	(92%)

of COVID-19), and high (>25%; e.g., symptomatic household contacts of patients with COVID-19) [10]. In addition to the predictive values for single tests, we also evaluated orthogonal testing algorithms that sequentially combined the test characteristics of two tests according to the method proposed by the Food and Drug Administration (FDA) and the Centers of Disease Control (CDC) in the United States of America [13, 14]. Predictive values were rounded to integers. *P* values < 0.05 were considered statistically significant. Statistical computations were performed with MedCalc version 18.11.3 (Mariakerke, Belgium). Graphs were drawn with Microsoft Excel 2016 MSO (16.0.8431.2046) (Microsoft Inc., Seattle, USA) using the linear interpolation function.

3. Results

3.1. Sensitivity. Two hundred sixty-eight samples from 180 patients were available. The median age at diagnosis was 56 years IQR [38, 72]. Not all samples were tested with all tests. The number of tested samples and the number of positive samples are presented in Table 2. The rates of positive samples over the different weeks are illustrated in Figure 1. Figure 1(a) shows the positivity rates of the chemiluminescence assays, and all three investigated formats had the highest positivity rate during the 3rd week after the clinical presentation. After this period, the positivity rates for all three investigated assays decreased to approximately 92% and remained stable. For the ELISAs, a peak was also observed at week 3 for IgG and IgM, whereas the peak for IgA occurred at week 5. IgG exhibited a different behavior, according to the test manufacturer. Although the EI positivity rate remained constant after 9 weeks, the positivity rate of EDI decreased by approximately 40%. The IgM positivity rate decreased even further to approximately 15%. IgA also showed a decrease in the positivity rate to approximately 80%. In the LFIA, IgM showed an earlier increase in positivity rates than IgG, with IgG and IgM positivity rates peaking at a value of approximately 80% at week 3. Notably, the LFIA displayed a significantly higher sensitivity than the LIA, the EI IgG ELISA, and the EDI IgM ELISA (78 vs. 50%, P = 0.02; vs. 36%, P = 0.004; vs. 53%; P = 0.04) at week 2. The positivity rate of IgM decreased to 30% after 9 weeks, whereas the IgG positivity rate decreased to 70%. The LFIA test format reporting combined reaction of both IgG and IgM showed a positivity rate of approximately 90% at week 3, which decreased to somewhat lower values at week 9.

3.2. Predictive Values of Single Tests. Predictive values were calculated as a function of pretest probabilities encountered in the clinical routine (i.e., 1% to 40%) to determine the effect of the different diagnostic characteristics at different time points of blood sample collection on the operational test characteristics [10]. Figure 2 illustrates the positive predictive values (PPVs) at different time points, whereas negative predictive values (NPVs) are presented in Figure 3.

The chemiluminescence assays displayed good predictive characteristics in excluding COVID-19 with a negative test result if the sample was collected at week 3 or thereafter. In situations with a moderate to high pretest probability, none of the chemiluminescence assays would be capable of excluding a COVID-19 infection during the first two weeks of a suspected infection. A positive test result obtained using CMIA and LIA for asymptomatic patients with a very low and low pretest probability had a PPV of less than 95%, regardless of the time point at which the blood sample was




FIGURE 1: Positivity rates of 10 tests in 8 assays over a period of 9 weeks: (a) chemiluminescence assays, (b) ELISAs, and (c) LFIA.

collected. Positive results obtained using the ECLIA at various sampling time points from patients with a low pretest probability of at least 5% had a PPV > 95% for the prediction of COVID-19.

Regarding the ELISAs, the operational test characteristics of the assay from one manufacturer are better than the assay from another manufacturer. The EDI IgG and IgM ELISAs, however, generally showed low PPVs during the first two weeks and thereafter in low pretest probability settings, independent of the blood sampling time point. The ability of the EI ELISAs to exclude COVID-19 during the first two weeks with an NPV of 95% or greater is possible only in patients with very low and low pretest probabilities. Thereafter, the exclusion of COVID-19 with a negative test result was able to be relatively safely conducted in samples from patients with higher pretest probabilities. The EDI IgG ELISA excluded COVID-19 with NPVs > 95% for patients with very low, low, and moderate pretest probabilities, whereas the IgM assay cannot be reliably used in this context. Regarding a positive diagnosis of COVID-19, neither EDI ELISAs appeared to add valuable information in any situation when used as single tests.

The LFIA IgG measurement appeared to possess the potential for diagnosing COVID-19 in patients with moderate and higher pretest probabilities, but not in patients with very low and low pretest probabilities, when blood samples were collected at least 3 weeks after symptom onset. Positive LFIA IgM results did not display a useful PPV in predicting COVID-19. The combined judgment of both IgG and IgM LFIA tests was not useful in reliably predicting COVID-19. The combined LFIA test possessed an NPV of \geq 95% in excluding COVID-19 in patients with very low and low pretest probabilities (i.e., symptomatic and asymptomatic patients), regardless of the time of sampling. At week 3 or thereafter, the NPV also reached values of \geq 95% for patients with moderate pretest probabilities. Together, the LFIA appeared to exclude COVID-19 in patients with low pretest probabilities throughout the disease course with negative combined IgG/IgM results. Furthermore, LFIA IgG tests also excluded COVID-19 in patients with a moderate pretest probability at week 3 after the first clinical presentation and thereafter.

3.3. Orthogonal Testing Algorithms. In addition to the IgM ELISA, all investigated tests provided relatively high NPVs in excluding COVID-19 in patients with negative test results and low to moderate pretest probabilities over the whole 9 weeks. With the exception of the ECLIA, the PPVs were less than 95% for individuals with low pretest probabilities over the whole 9 weeks. Chemiluminescence tests for patients with a moderate pretest probability provided PPVs \geq 95%, whereas the PPVs for ELISAs and LFIA were lower. We therefore determined the PPVs using an orthogonal testing approach, where positive results were confirmed with another independent test. The combination of two of the lowest performing tests for positive results in an orthogonal

5 10 15	38 56 67	46 64 74	49 67 77	48 66 76	48 66 75	44 63 73	47 65 75	39 58 69	48 66 76
				10	10		17		
Pretest probability (%)	0-6 days 11	7-13 days 14	14-20 days 16	21-27 days 15	28-34 days 15	35-41 days 13	42-48 days 15	49-55 days 11	>55 da 15
LFIA Ig	0.6 daw	7-12 dam	14-20 daw	21,27 daw	28-24 days	35.41 dave	42.49 daw	49,55 days	
30 40	84 89	88 92	88 92	88 92	86 90	76 83	79 86	55	74 81
10 15 20	57 68 75	65 75 81	66 76 82	65 75 81	61 71 78	45 56 65	50 61 69	24 33 42	42 53 62
1 5 10	11 39	15 47	15 48	14 47	12 42	7 28	8 32	3 13	6 25
Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 da
LFIA IgM									
	70	70	13		17	.,,	33	17	
20 30 40	95 97 98	97 98	97 99 99	98 99 99	97 99 99	97 98 99	97 98 99	97 98 99	97 98 99
15 20	90 94 95	94 96	95 96 97	93 97 98	95 96 97	95 96 97	96	95 97	96
1 5 10	45 81 90	48 83 91	89 95	89 95	89 95	87 93	89 94	93	88 94
Pretest probability (%)	0-6 days 45	7-13 days 48	14-20 days 61	21-27 days 61	28-34 days 61	35-41 days 56	42-48 days	49-55 days 53	>55 da 59
LFIA IgG									
30 40	89 92	87 91	93 95	85 90	85 90	80 86	81 87	68 77	62 72
15 20	76 82	74 80	84 88	69 76	70 77	63 70	63 71	46 55	40 49
5 10	49 67	46 64	60 76	40 59	41 59	33 51	34 52	21 35	17 30
Pretest probability (%)	0-6 days 16	7-13 days	14-20 days 23	21-27 days	28-34 days	35-41 days 9	42-48 days	49-55 days 5	>55 da
EDI IgM ELISA	0.61	7.12	14.20	21.25	20.21	25 41	42.42.1	40.52	
EDI I-M ELICA									
30 40	88 92	88 92	91 94	91 94	90 93	89 93	89 92	88 92	86 90
15 20	74 80	76 82	81 86	81 86	79 84	77 83	76 82	75 81	71 78
5 10	46 64	48 66	56 73	56 73	53 70	50 68	49 67	47 65	42 61
Pretest probability (%) 1	0-6 days 14	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days 14	>55 da
EDI IgG ELISA			14.00	01.05.	20.2.3		10.17	10.55	
EDI IoC FLICA									
30 40	96 98	97 98	98 98	98 99	98 99	98 99	98 99	98 98	98 99
15 20	91 94	93 95	94 96	95 97	95 97	95 96	95 96	94 96	95 96
5 10	76 87	81 90	83 91	86 93	86 93	84 92	85 92	83 91	84 92
1	38	44	49	53	54	51	52	49	51
Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 da
EI IgA ELISA									
30 40	96 98	95 97	98 99	98 99	98 99	98 99	98 99	98 99	98 99
15 20 30	91 94 96	89 92 95	96 97 98	95 97 98	95 97 98	95 97 98	95 97 98	95 96 98	96 97 98
5	76 87	71 84	87 93	86 93	86 93	85 92	86 93	85 92	87 93
1	38	32	56	53	54	53	53	52	55
Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 da
EI IgG ELISA									
40	99	99	99	99	100	99	100	99	100
20 30 40	98 99	98 99	99 99	99 99	99 99	99 99	99 99	99 99	99 99
10 15	95 97	95 97	97 98	97 98	97 98	97 98	97 98	97 98	97 98
1 5	64 90	63 90	75 94	74 94	76 94	74 94	76 94	74 94	76 94
Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 da
LIA									
40	100	100	100	100	100	100	100	100	100
20 30 40	100 100	100 100	100 100 100	100	100 100 100	100 100 100	100 100 100	100	100 100 100
10 15 20	99 99 99	99 99 99	99 99 100	99 99 100	99 99 100	99 99 100	99 99 100	99 99 100	99 99 100
1 5 10	86 97	87 97	91 98	91 98	91 98	90 98	91 98	91 98	90 98
Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 da
ECLIA									
30 40	98 99	98 99	99 99	99 99	99 99	99 99	99 99	99 99	99 99
15 20	96 97	96 97	97 98	97	97 98	97	97 98	97 98	97 98
		93	96	96	96	96	95	95	95
1 5 10	55 87 93	55 87	91	91	91	91	91	91	91

FIGURE 2: Heat maps of positive predictive values (PPVs) of different tests used to predict COVID-19 stratified according to the pretest probabilities and sampling time after the first clinical presentation. The predictive values were colored as follows: 99 and 100% dark blue, 95% to 98% lighter blue, 90% to 94% white, 80% to 89% light yellow, 70% to 79% medium yellow, 60% to 69% dark yellow, 50% to 59% light red, 30% to 49% middle red, and less than 30% dark red.

CMIA

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	100	100	100	100	100	100	100	100	100
5	98	98	100	100	100	100	100	100	100
10	96	96	100	100	100	100	99	99	99
15	94	93	100	99	99	99	99	99	99
20	91	91	100	99	99	99	98	98	98
30	86	86	100	98	98	99	97	97	97
40	79	79	100	97	98	98	96	95	95

ECLIA

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	100	100	100	100	100	100	100	100	100
5	98	98	100	100	100	100	100	100	100
10	96	97	100	99	100	99	100	99	99
15	94	95	100	99	99	99	100	99	99
20	91	93	100	99	99	99	99	99	98
30	86	88	100	98	99	98	99	98	97
40	80	83	100	97	98	96	99	97	95

LIA

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	100	99	100	100	100	100	100	100	100
5	98	97	99	99	100	99	100	99	100
10	95	95	99	98	99	98	100	98	99
15	92	92	98	98	99	97	99	97	99
20	89	89	97	97	98	96	99	96	98
30	83	82	95	94	97	94	98	94	97
40	76	75	93	91	95	91	97	90	95

EI IgG ELISA

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
	99	99	100	100	100	100	100	100	100
5	97	97	100	99	100	99	99	99	100
10	94	93	100	99	99	99	99	98	100
15	92	90	100	98	99	98	98	97	100
20	88	86	100	98	99	97	97	96	99
30	82	79	100	96	98	95	96	94	99
40	74	70	100	94	96	93	94	90	98

EI IgA ELISA

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	99	100	100	100	100	100	100	100	100
5	97	98	99	99	100	99	99	99	99
10	94	96	97	99	99	98	98	97	98
15	92	94	96	98	99	97	97	96	97
20	88	92	94	98	98	95	96	94	95
30	82	86	90	96	97	92	94	91	93
40	74	80	86	94	96	89	90	86	89

FIGURE 3: Heat maps of negative predictive values (NPVs) of different tests used to predict COVID-19 stratified according to the pretest probabilities and sampling time after the first clinical presentation. The predictive values were colored as follows: 99 and 100% dark blue, 95% to 98% lighter blue, 90% to 94% white, 80% to 89% light yellow, 70% to 79% medium yellow, and 60% to 69% dark yellow.

testing algorithm, i.e., the LFIA IgG/IgM test followed by the EDI IgG ELISA test, for patients with a moderate pretest probability consistently provided PPVs of ≥95%, as shown in Figure 4. A combination of two chemiluminescence tests (i.e., CMIA followed by LIA) provided PPVs of 100% for patients with all pretest probabilities (Figure 4). Other test combinations (i.e., ECLIA/EDI IgG, ECLIA/LIA, ECLIA/C-MIA, ECLIA/EI IgG, CMIA/EDI IgG, CMIA/EI IgG, LIA/EDI IgG, and LIA/EI IgG) provided comparable PPVs (≥99%) to the CMIA/LIA combination throughout the whole 9-week period for patients with all pretest probabilities (data

not shown). NPVs of a CMIA/LIA combination were lower than those of the CMIA or the LIA alone, as shown in Figure 5. Other combinations of negative test results exhibited similar performance and are not shown.

4. Discussion

A recent Cochrane review stated that data available for diagnostic characteristics of SARS-CoV-2 antibody assays for more than 35 days after symptom onset are insufficient [3]. The present study provides data for a variety of tests beyond

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
						· · · · · · · · · · · · · · · · · · ·			
1	100	100	100	100	100	100	100	100	100
5	98	99	100	100	99	99	99	98	98
10	96	97	100	100	99	98	97	97	95
15	95	96	100	100	98	96	96	95	93
20	92	94	100	100	97	95	94	93	90
30	88	90	100	100	96	92	91	88	84
40	82	85	100	100	93	88	86	83	78

EDI IgM ELISA

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	100	100	100	99	99	99	99	99	99
5	98	98	100	97	97	96	96	96	95
10	96	95	99	94	94	93	93	91	91
15	93	92	99	90	91	89	89	87	86
20	91	89	99	87	87	85	85	82	82
30	85	83	98	80	80	77	77	73	72
40	78	76	97	72	72	68	68	63	62

LFIA IgG

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	99	99	100	100	100	100	100	100	100
5	97	97	99	99	99	98	99	98	99
10	94	94	98	98	98	96	97	95	97
15	91	91	96	96	96	94	96	93	95
20	87	88	95	95	95	92	94	90	93
30	80	81	91	92	91	87	91	84	89
40	72	73	87	88	87	81	86	77	84

LFIA IgM

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	100	100	100	100	100	99	99	99	99
5	97	99	99	99	98	96	97	95	96
10	95	97	97	97	96	93	93	91	92
15	92	95	96	95	93	89	90	86	88
20	89	94	95	94	91	85	86	81	84
30	83	90	91	89	85	77	79	72	76
40	75	85	87	85	79	68	70	62	67

LFIA Ig

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	>55 days
1	100	100	100	100	100	100	100	100	100
5	98	99	99	99	99	98	99	98	99
10	95	97	99	98	98	97	98	95	98
15	92	96	98	97	97	95	97	93	97
20	90	94	97	96	96	93	95	90	96
30	83	91	95	93	93	89	92	85	94
40	76	86	93	90	90	84	89	78	91

FIGURE 4: PPVs obtained for the combinations of two assays performed according to the orthogonal testing algorithm recommended by the FDA and CDC. The predictive values were colored as follows: 99 and 100% dark blue, 95% to 98% lighter blue, 90% to 94% white, 80% to 89% light yellow, 70% to 79% medium yellow, and 60% to 69% dark yellow.

9 weeks (63 days). We confirm that the investigated tests have insufficient test characteristics, particularly for positive results, two weeks after the first clinical presentation, with one exception. The combination of tests in an orthogonal testing algorithm, even tests with suboptimal test characteristics, for positive results provided PPVs \geq 95% for individuals with moderate and high pretest probabilities early in the course of the infection. Furthermore, positivity rates appeared to be stable for chemiluminescence assays testing for total Ig and IgG, whereas the positivity rates of IgM tests decreased over time.

Fenwick and colleagues and others observed sensitivities than the present study in the ECLIA (95.6%), LIA (88.9%), EI IgG (88.9%), and EDI IgG (76.7%), which corroborates our findings derived in smaller cohorts stratified according to time after the first clinical presentation of COVID-19 [15–18]. The sensitivity of the CMIA described by Tang et al. (93.8%) is comparable to the sensitivity values observed in our study [18]. The sensitivity of the LFIA was also comparable to the values reported for other LFIA test formats (75% in the second week and 90% thereafter) [19]. Some test formats analyzed in our study had stable sensitivities over a LFIA Ig and EDI IgG

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	s >55 days
1	65	74	81	80	78	73	75	67	71
5	91	94	96	95	95	94	94	91	93
10	95	97	98	98	98	97	97	96	96
15	97	98	99	99	98	98	98	97	98
20	98	99	99	99	99	99	99	98	98
30	99	99	99	99	99	99	99	99	99
40	99	100	100	100	100	100	100	99	99

CMIA Ig and LIA IgG

Pretest probability (%)	0-6 days	7-13 days	14-20 days	21-27 days	28-34 days	35-41 days	42-48 days	49-55 days	s >55 days
1	100	100	100	100	100	100	100	100	100
5	100	100	100	100	100	100	100	100	100
10	100	100	100	100	100	100	100	100	100
15	100	100	100	100	100	100	100	100	100
20	100	100	100	100	100	100	100	100	100
30	100	100	100	100	100	100	100	100	100
40	100	100	100	100	100	100	100	100	100

FIGURE 5: NPVs obtained for the combination of the CMIA and LIA for samples with an initial negative test result using an orthogonal test algorithm. NPVs of the test combination are lower than either single test. The predictive values were colored as follows: 90% to 94% white, 80% to 89% light yellow, 70% to 79% medium yellow, 60% to 69% dark yellow, 50% to 59% light red, 30% to 49% middle red, and less than 30% dark red.

duration of 9 weeks after the first clinical presentation. Other test formats, particularly tests measuring IgM and IgA, as well as an ELISA measuring IgG directed against the nucleocapsid antigen, showed decreasing positivity rates over time. We consider the use of test formats with decreasing sensitivities over time problematic, as long as they do not employ modified cut-off values, which should be further investigated in larger cohorts.

In clinical diagnostics, the operational characteristics rather than the diagnostic characteristics are of interest. In our opinion, the use of heat maps to illustrate diagnostic strengths and weaknesses in certain situations according to the time since the first clinical presentation and pretest probability is useful, particularly when only one test is employed. To the best of our knowledge, heat maps have not yet been introduced as a tool to interpret serological assays of infectious diseases [4]. Unfortunately, at the moment, there is no clinical score currently available to assess pretest probability, which relies on a history of clinical symptoms alone and could also be utilized retrospectively (e.g., because no laboratory results are available at the time when a patient was symptomatic) [20]. However, other rough estimates also allow for assessment of pretest probability and clinical use of the heat maps according to the individual situation of a patient: symptomatic patients have a pretest probability of 10% and higher, asymptomatic patients usually have a pretest probability of less than 10%, and close contacts of patients with confirmed COVID-19 cases have a pretest probability of 15-30% [10]. Seroprevalence data of a region can also help to assess the pretest probability even in the absence of clinical symptoms.

Positive predictive values differed among the different test formats. Based on the results of our study, chemiluminescence formats have somewhat better operative characteristics than at least some of the investigated ELISA and LFIA test formats. Furthermore, the SARS-CoV-2 IgM test should be used with caution to assess an immune response to COVID-19 that has already been apparent for longer than 21 days. This result is consistent with the findings of Coste et al., who, because of the simultaneous occurrence with IgG, judged IgM to be of no value in diagnosing acute or subacute SARS-CoV-2 infections [21]. Our study clearly illustrates that an orthogonal testing approach adds valuable diagnostic information. The combination of two of the lowest performing assays according to the approach recommended by FDA and CDC for moderate pretest probabilities provided PPVs > 95% throughout the 9 weeks after the first clinical presentation. These characteristics further improved and were extended to low prevalence settings when the chemiluminescence and EI IgG assays were combined. Our study confirms that an orthogonal testing approach for initially positive samples adds diagnostic value.

After two weeks, negative predictive values of tests investigating IgG or total Ig were \geq 95% in patients with very low, low, and moderate probabilities. Chemiluminescence assays displayed a somewhat higher predictivity than ELISAs and LFIA. Importantly, the LFIA reading for both IgM and IgG bands showed greater predictive value than reading either of the two bands alone. However, in contrast to the practice of confirming positive test results with an alternative test, the application of an orthogonal testing approach is not useful in a sample with an initially negative test result. NPVs were worse than the initial index test.

Our study has several strengths and limitations. One strength is that we were able to study positivity rates over 9 weeks. Another strength is that we studied 8 different assays employing the commonly used measurement principles, i.e., chemiluminescence, ELISA, and lateral flow immunoassay. A limitation is that the day of onset of clinical symptoms was not available. Instead, we recorded the first date of clinical presentation for COVID-19. In Liechtenstein and Switzerland, all symptomatic patients are tested for COVID-19 using PCR. Due to the high accessibility of testing in COVID-19 testing centers, patients presented to these centers very rapidly after the onset of symptoms. Additionally, our data, particularly the results obtained within the first 35 days, are similar with the findings described elsewhere using the onset of symptoms as the reference time point[3, 18, 22]. Some studies have also presented data using PCR testing as a reference time point [18, 22]. We therefore propose that our approach of using the first clinical presentation for COVID-19 testing in the investigated setting is a good proxy for the onset of symptoms. When analyzing the different time strata, the sample size of the included samples was not large, and not all sera were tested with all tests, which might result in relatively imprecise point estimates of sensitivity. The sample sizes are comparable to the values reported in other studies, and the sensitivities identified in our setting are comparable to the values reported in larger other studies, suggesting that relatively small sample sizes do not invalidate our findings [3, 15, 17, 18, 21, 22]. Finally, even if we did not have a detailed clinical description of the patients, we know that the samples of our patients originated from outpatient settings. Thus, it can be assumed that the included confirmed symptomatic patients were with mild to moderate COVID-19 severity. Our findings might not apply to individuals with severe cases and an asymptomatic disease course [15, 23], which requires confirmation in further investigations. Our findings, however, provide valuable insights into interpreting past symptoms in patients who were not assessed using RT-PCR testing or who had a negative RT-PCR test, despite the presence of suggestive symptoms, at least within two months of clinical presentation.

In conclusion, we identified sensitivities for 8 different SARS-CoV-2 antibody tests in symptomatic patients over a period of 63 days. The investigated chemiluminescence assays did not exhibit a decrease in positivity rates over the investigated period. This finding was not observed for other test formats, e.g., IgM tested using ELISA or LFIA. Not all commercially available and CE-marked assays exhibit satisfactory predictive values for diagnosing or excluding COVID-19. In particular, predictive values were lower during the first two weeks after the first clinical presentation. An orthogonal test algorithm confirming positive, but not negative, results from a single test with an independent assay provided satisfactory positive predictive values, even for tests with less accurate performance. Orthogonal testing approaches for positive results should therefore be reinforced.

Data Availability

The data used to support the findings in this study will be available from the corresponding author upon request.

Disclosure

The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors' Contributions

Martin Risch was responsible for conceptualization, methodology, formal analysis, and writing of the original draft; Myriam Weber was responsible for conceptualization, methodology, and formal analysis; Sarah Thiel was responsible for data curation, validation, and resources; Kirsten Grossmann was responsible for resources; Kirsten Nadja Wohlwend was responsible for investigation, validation, and resources; Thomas Lung was responsible for validation and resources; Dorothea Hillmann was responsible for investigation, validation, project administration, and resources; Michael Ritzler was responsible for resources; Francesca Ferrara was responsible for resources; Susanna Bigler was responsible for validation and resources; Konrad Egli was responsible for validation and resources; Thomas Bodmer was responsible for validation and resources; Mauro Imperiali was responsible for validation and resources; Yacir Salimi was responsible for validation and resources; Felix Fleisch was responsible for resources; Alexia Cusini was responsible for resources; Harald Renz was responsible for conceptualization; Philipe Kohler was responsible for validation and writing of the original draft; Pietro Vernazza was responsible for conceptualization and writing of the original draft; Christian Kahlert was responsible for conceptualization, methodology supervision, resources, and writing of the original draft; Matthias Paprotny was responsible for supervision and resources; Lorenz Risch was responsible for conceptualization, methodology, funding acquisition, supervision, resources, and writing of the original draft. All authors were involved in writing, reviewing, and editing.

Acknowledgments

The assistance of Toni Schönenberger and Walter Frehner in identifying samples is acknowledged. The research project was funded by a grant from the government of the Principality of Liechtenstein.

References

- Z. Fritz, R. Huxtable, J. Ives, A. Paton, A. M. Slowther, and D. Wilkinson, "Ethical road map through the COVID-19 pandemic," *BMJ*, vol. 369, 2020.
- [2] N. Zhu, D. Zhang, W. Wang et al., "A novel coronavirus from patients with pneumonia in China, 2019," *The New England Journal of Medicine*, vol. 382, no. 8, pp. 727–733, 2020.
- [3] J. J. Deeks, J. Dinnes, Y. Takwoingi et al., "Antibody tests for identification of current and past infection with SARS-CoV-2," *Cochrane Database of Systematic Reviews*, vol. 6, article CD013652, 2020.
- [4] T. Struyf, J. J. Deeks, J. Dinnes et al., "Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease," *Cochrane Database of Systematic Reviews*, vol. 7, article CD013665, 2020.

- [5] L. M. Kucirka, S. A. Lauer, O. Laeyendecker, D. Boon, and J. Lessler, "Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure," *Annals of Internal Medicine*, vol. 173, no. 4, pp. 262–267, 2020.
- [6] G. Lippi, A. M. Simundic, and M. Plebani, "Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)," *Clinical Chemistry and Laboratory Medicine*, vol. 58, no. 7, pp. 1070–1076, 2020.
- [7] S. K. Vashist, "In vitro diagnostic assays for COVID-19: recent advances and emerging trends," *Diagnostics (Basel)*, vol. 10, no. 4, p. 202, 2020.
- [8] M. C. Weinstein, K. A. Freedberg, E. P. Hyle, and A. D. Paltiel, "Waiting for certainty on COVID-19 antibody tests — at what cost?," *New England Journal of Medicine*, vol. 383, no. 6, p. e37, 2020.
- [9] R. Patel, E. Babady, E. S. Theel et al., "Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: value of diagnostic testing for SARS– CoV-2/COVID-19," *mBio*, vol. 11, no. 2, 2020.
- [10] S. Thiel, M. C. Weber, L. Risch et al., "Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein - an observational study," *Swiss Medical Weekly*, pp. 150–w20361, 2020.
- [11] L. Risch, A. Monn, R. Luthy, H. Honegger, and A. R. Huber, "The predictive characteristics of D-dimer testing in outpatients with suspected venous thromboembolism: a Bayesian approach," *Clinica Chimica Acta*, vol. 345, no. 1-2, pp. 79– 87, 2004.
- [12] P. Kohler, C. R. Kahlert, J. Sumer et al., "Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers-results of a prospective cohort study," *Infection Control and Hospital Epidemiology*, pp. 1–5, 2020.
- [13] Centers for Disease Prevention and Control, "Interim guidelines for COVID-19 antibody testing," 2020, June 6, https:// www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibodytests-guidelines.html.
- [14] U.S. Food and Drug Administration, "EUA authorized serology test performance," 2020, July 2020, https://www.fda.gov/ medical-devices/emergency-situations-medical-devices/euaauthorized-serology-test-performance.
- [15] C. Fenwick, A. Croxatto, A. T. Coste et al., "Qualitative changes in the SARS-CoV-2 antibody response in the postinfection phase impact the estimates of infections in population-based seroprevalence studies," *medRxiv*, 2020, 2020.07.14.20153536.
- [16] P. Muench, S. Jochum, V. Wenderoth et al., "Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2," *Journal of Clinical Microbiology*, vol. 58, no. 10, 2020.
- [17] T. Perkmann, N. Perkmann-Nagele, M.-K. Breyer et al., "Sideby-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity," *Clinical Chemistry*, vol. 66, no. 11, pp. 1405–1413, 2020.
- [18] M. S. Tang, K. G. Hock, N. M. Logsdon et al., "Clinical performance of the Roche SARS-CoV-2 serologic assay," *Clinical Chemistry*, vol. 66, no. 8, pp. 1107–1109, 2020.
- [19] I. Montesinos, D. Gruson, B. Kabamba et al., "Evaluation of two automated and three rapid lateral flow immunoassays

for the detection of anti-SARS-CoV-2 antibodies," *Journal of Clinical Virology*, vol. 128, article 104413, 2020.

- [20] C.-Y. Song, J. Xu, J.-Q. He, and Y.-Q. Lu, "COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients," *medRxiv*, 2020.
- [21] A. T. Coste, K. Jaton, M. Papadimitriou-Olivgeris, G. Greub, and A. Croxatto, "Comparison of SARS-CoV-2 serological tests with different antigen targets," *medRxiv*, 2020.
- [22] M. S. Tang, K. G. Hock, N. M. Logsdon et al., "Clinical performance of two SARS-CoV-2 serologic assays," *Clinical Chemistry*, vol. 66, no. 8, pp. 1055–1062, 2020.
- [23] F. Hamilton, P. Muir, M. Attwood et al., "Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assay," *Journal of Infection*, 2020.